Saturday 17 October 2026
Export A’s income statement to Excel — free account
Agilent Technologies, Inc.
A Healthcare Diagnostics & Research
Agilent Technologies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $6.9 billion, up 6.73% from fiscal 2024. In the quarter to July 2026, revenue grew 8.06%, EPS grew 8.47%, free cash flow grew 69.5% and total debt rose 8.81%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
172.96
2.59
−1.48%
Follow A
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
27.18 | 23.16 | 29.82 | 31.96 |
+8 more quarters Free account |
P/S ratio |
5.29 | 4.51 | 5.42 | 5.98 | |
P/FCF ratio |
30.75 | 29.92 | 38.51 | 36.02 | |
P/Operating CF |
75.18 | 117.64 | 142.97 | 76.27 | |
P/B ratio |
5.30 | 4.58 | 5.55 | 6.17 | |
Price to Tangible BV |
27.34 | 14.61 | 19.18 | 22.80 | |
EV/Sales |
5.55 | 4.68 | 5.61 | 6.16 | |
EV/EBITDA |
21.42 | 18.47 | 22.78 | 24.24 | |
EV/Operating CF |
25.42 | 23.30 | 28.37 | 27.47 | |
EV/FCF |
32.24 | 31.06 | 39.81 | 37.11 | |
Quick Ratio |
1.41 | 1.46 | 1.47 | 1.40 | |
Current Ratio |
2.05 | 2.10 | 2.07 | 1.96 | |
Net Debt/EBITDA |
3.70 | 2.67 | 3.08 | 2.45 | |
Debt/Assets |
26.10% | 23.35% | 23.80% | 23.96% | |
Debt/Equity |
0.50 | 0.43 | 0.44 | 0.45 | |
Asset Turnover |
0.56 | 0.57 | 0.57 | 0.57 | |
Operating CF/Net income |
1.43 | 0.82 | 0.88 | 1.26 | |
Capex/Depreciation |
(1.21) | (1.13) | (1.39) | (1.31) | |
Interest Coverage |
15.31 | 15.96 | 14.12 | 16.41 | |
Research and Development Expense of Revenue |
6.55% | 6.87% | 6.51% | 6.39% | |
Selling, General and Administrative Expense of Revenue |
25.29% | 25.34% | 26.47% | 23.00% | |
Intangible Assets out of Total Assets |
0.43 | 0.37 | 0.38 | 0.39 | |
Share Based Compensation of Revenue |
1.70% | 1.74% | 2.28% | 1.40% | |
Graham Net Nets |
(0.05) | (0.04) | (0.03) | (0.03) | |
Graham Number |
54.68 | 53.25 | 49.93 | 49.46 | |
Earnings Yield |
3.68% | 4.32% | 3.35% | 3.13% | |
Free Cash Flow Yield |
3.25% | 3.34% | 2.60% | 2.78% | |
Revenue per Share |
6.66 | 6.51 | 6.35 | 6.55 | |
Operating CF per Share |
1.84 | 0.98 | 0.95 | 1.92 | |
Capex per Share |
(0.28) | (0.27) | (0.33) | (0.33) | |
Free Cash Flow per Share |
1.56 | 0.71 | 0.62 | 1.59 | |
Cash per Share |
6.23 | 6.41 | 6.21 | 6.30 | |
Shareholders Equity per Share |
26.11 | 25.26 | 24.41 | 23.74 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
26.11 | 25.26 | 24.41 | 23.74 | |
Free Cash Flow |
439.00 | 201.00 | 175.00 | 452.00 | |
Working Capital |
2,404.00 | 2,494.00 | 2,381.00 | 2,247.00 | |
Capital Expenditures |
(80.00) | (76.00) | (93.00) | (93.00) | |
Net Current Asset Value |
(1,911.00) | (1,180.00) | (1,290.00) | (1,392.00) | |
EV/EBIT |
24.96 | 21.76 | 27.20 | 28.96 | |
Capex to Sales |
0.04 | 0.04 | 0.05 | 0.05 | |
Price to Operating Income |
23.81 | 20.96 | 26.32 | 28.10 | |
| Other line items | |||||
Average Receivables |
1,430.00 | 1,432.00 | 1,424.50 | 1,405.50 | |
Average Payables |
569.00 | 566.00 | 574.50 | 555.00 | |
Average Inventory |
1,065.50 | 1,040.00 | 1,028.00 | 998.50 | |
Average Assets |
13,096.50 | 12,611.50 | 12,363.50 | 12,286.50 | |
Average Common Equity |
6,866.50 | 6,629.00 | 6,467.50 | 6,319.50 |
Columns are period end dates